Profile data is unavailable for this security.
About the company
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
- Revenue in USD (TTM)0.00
- Net income in USD-112.90m
- Incorporated2006
- Employees121.00
- LocationAdverum Biotechnologies Inc100 Cardinal WayREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 649-1004
- Fax+1 (650) 329-8151
- Websitehttps://adverum.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ProQR Therapeutics NV | 14.49m | -28.84m | 133.90m | 157.00 | -- | 3.71 | -- | 9.24 | -0.3552 | -0.3552 | 0.1785 | 0.4441 | 0.0957 | -- | -- | 92,302.80 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 134.13m | 127.00 | -- | 1.69 | -- | 26.83 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
| Quantum-Si Inc | 1.29m | -91.82m | 135.02m | 159.00 | -- | 0.5321 | -- | 105.08 | -0.6482 | -0.6482 | 0.0091 | 1.79 | 0.004 | 0.196 | 7.93 | 8,081.76 | -28.67 | -- | -29.50 | -- | 49.26 | -- | -7,145.76 | -- | 30.03 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -51.69m | 135.45m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -22.53m | 135.46m | 10.00 | -- | -- | -- | -- | -1.03 | -1.03 | 0.00 | -0.1181 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 136.38m | 51.00 | -- | 0.5205 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
| TriSalus Life Sciences Inc | 21.98m | -68.07m | 137.43m | 112.00 | -- | -- | -- | 6.25 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 137.52m | 179.00 | -- | 0.5878 | -- | 1.41 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Context Therapeutics Inc | 0.00 | -21.32m | 138.00m | 5.00 | -- | 3.48 | -- | -- | -1.34 | -1.34 | 0.00 | 0.5288 | 0.00 | -- | -- | 0.00 | -99.14 | -- | -114.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Galectin Therapeutics Inc | 0.00 | -44.78m | 141.70m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
| Adverum Biotechnologies Inc | 0.00 | -112.90m | 141.98m | 121.00 | -- | 0.7788 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Caribou Biosciences Inc | 33.40m | -115.26m | 144.51m | 158.00 | -- | 0.4209 | -- | 4.33 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -29.69m | 145.88m | 10.00 | -- | 1.70 | -- | -- | -0.2359 | -0.2359 | 0.00 | 0.6833 | 0.00 | -- | -- | 0.00 | -28.65 | -29.97 | -29.84 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 147.84m | 147.00 | -- | -- | -- | 1.23 | -1.13 | -1.13 | 6.90 | -1.81 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Puma Biotechnology Inc | 226.63m | 15.38m | 149.54m | 185.00 | 9.63 | 2.93 | 5.56 | 0.6599 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Capricor Therapeutics Inc | 27.10m | -24.31m | 150.15m | 101.00 | -- | 8.09 | -- | 5.54 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
Data as of Jul 02 2024. Currency figures normalised to Adverum Biotechnologies Inc's reporting currency: US Dollar USD
35.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Logos Global Management LPas of 31 Mar 2024 | 1.50m | 7.23% |
| BML Capital Management LLCas of 18 Apr 2024 | 1.05m | 5.06% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 900.53k | 4.34% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 899.51k | 4.33% |
| Franklin Advisers, Inc.as of 31 Mar 2024 | 675.68k | 3.26% |
| Commodore Capital LPas of 31 Mar 2024 | 657.33k | 3.17% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 554.45k | 2.67% |
| Laurion Capital Management LPas of 31 Mar 2024 | 438.94k | 2.12% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 416.67k | 2.01% |
| Assenagon Asset Management SA (Germany)as of 31 Mar 2024 | 358.72k | 1.73% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
